Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
5000
Clinical Trial Start Date
October 19, 2021
0Primary Completion Date
January 1, 2024
0Study Completion Date
June 1, 2024
0Clinical Trial Study Type
Observational0
Observational Clinical Trial Type
Cohort0
Observational Study Perspective
Retrospective0
Official Name
Pharmaco-epidemiological Study of COVID 19 Vaccines in Patients Undergoing Immunotherapy for Cancer. A Retrospective Open Cohort Study0
Last Updated
February 1, 2022
0Study summary
The investigators wish to set up a pharmaco-epidemiological cohort within the Hospital Territorial Groups of the Cévennes-Gard Camargue, East-Hérault and Haute-Garonne and West Tarn on a specific population, patients undergoing immunotherapy for cancer, as currently there is no data available under "real life" conditions following anti-COVID vaccination19. The hypothesis is that patients undergoing immunotherapy will not develop more vaccine-related adverse events than those observed in the efficacy and safety validation studies of the BNT162b2 mRNA Covid-19, mRNA-1273 SARS CoV-2, Oxford/AstraZeneca and Ad26COV2.S, JMJ Vaccine or J \& J COVID-19 Vaccine.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
